Robert Klein, Art Torres and Jonathon Thomas. Photo courtesy of the California Stem Cell ReportThe man considered to be the father of the $12 billion California stem cell agency popped up in the news twice this month, once in a $38 million Sacramento lawsuit and then again as the host this month of a Biden campaign fundraiser whose tickets cost as much as $100,000.
A research scientist examines a capsule with a DNA double helix. (Photo: Dan Race, via Shutterstock)One year ago this month, a $5.5 billion wave washed over California’s ambitious stem cell agency and left it refreshed and renewed for another decade or so of searching for “miraculous” treatments for a host of deadly, incurable afflictions. It is now on a pace to hand out $38,000 an hour, 24 hours a day, seven days a week. That would amount to $519 million in awards between this time last year and the end of the agency’s current fiscal year in June.
Two of the members of the CIRM governing board, Chair Jon Thomas and Vice Chair Art Torres, during an earlier meeting.(Photo: CIRM)Directors of the $12 billion California stem cell agency have moved to weaken conflict of interest provisions affecting its governing board — eliminating “leave-the-room” requirements that are used by most private nonprofits to assure the integrity of their operations.
Robert Klein, left, and CIRM board member Jeff Sheey, right. At center is Board Vice Chair Art Torres. (Photo: California Stem Cell Report)The two men once worked together over the last 16 years to spend $3 billion in state funds on stem cell research in California. This week, however, they were very publicly on opposite sides of a ballot initiative to spend $5.5 billion more. The initiative is Proposition 14, which would require the state to borrow the additional billions.
Personnel at UCSF's facility in Fresno, which may benefit if Proposition 14 is approved. (Photo: UCSF)Proposition 14, the fall ballot measure to save California’s stem cell agency from financial extinction, contains much, much more than the $5.5 billion that it is seeking from the state’s voters. Added to the agency’s charter would be research involving mental health, “therapy delivery,” personalized medicine and “aging as a pathology.“ That is not to mention a greater emphasis on supporting “vital research opportunities” that are not stem cell-related.
A laboratory stem cell researcher uses a laptop in conjunction with a microscope. (Photo: moreimages, via Shutterstock)A small firm in Menlo Park, Ca., is probably the only company in the nation that is named after the number of a particular human protein. It is a small number too, only 47. But it has large implications for California’s financially strapped state stem cell agency.
Robert Klein at a November 2017 meeting of CIRM directors. (Photo: California Stem Cell Report)The man regarded as the father of the $3 billion California stem cell agency is thinking about changes in the program to help win voter approval of another $5 billion for the research program. They include a stronger requirement to make state-backed, stem cell therapies more affordable and accessible and to provide more cash for creating a greater stem cell work force in the Golden State.
An illustration of stem cells used in research. (Photo: Billion Photos, via Shutterstock)California’s $3 billion stem cell research agency, which is facing its financial demise in a few short years, has formed a team of its directors to tackle transition planning and examine possible alternatives, including ones that would extend its life. The first meeting of the group of directors is tentatively scheduled for Sept. 18.
A human DNA complex. ((Illustration, Shutterstock)The man often called the father of the California stem cell agency has all but said he is set to launch an effort to pump an additional $5 billion in state funding into the research effort, which is scheduled to run out of cash in about three years.